Zimberelimab

赛帕利单抗

Report date: 2026/03/21 20:00:21

Base Information

Drug NameZimberelimab
Drug Alias NameZimbirelimab誉妥YUTUOAB-122GLS-010 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsHormone-Resistant Prostate Neoplasms +[33] 
Global Approved IndicationsHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2021/08/25
Country/TerritoryBelgiumCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWuxi Biologics (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGilead Sciences IncThe First Affiliated Hospital With Nanjing Medical UniversityTaiho Pharmaceutical Co Ltd +[8] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsHormone-Resistant Prostate Neoplasms +[30] 
Inactive IndicationsLiver NeoplasmsTriple Negative Breast NeoplasmsNeoplasms

Other Information

ATC CodeL01XC
Related LinksDrugBankKEGG